


b.) Remarks

The claims have been amended for better format and to better recite the patentable nature of the present invention. For the Examiner's convenience, claim 10 mirrors claim 1 except for further limiting the subject matter of X<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup>. No new matter has been added.

As understood, in the outstanding Office Action, the Examiner is requiring that Applicants elect for prosecution a single disclosed compound to which the claims will be restricted. This requirement is respectfully traversed, to the extent the claims share the common structural feature as discussed below.

That is, as the Examiner correctly notes, all alternative compounds have methods (whether methods of administration or producing compounds) having the

common core structure  which methods are simply not taught or suggested by the


prior art.

Nonetheless, to satisfy 37 C.F.R. §1.143, Applicants hereby elect a group containing compound 4.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,



Attorney for Applicants  
Lawrence S. Perry  
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200

NY\_MAIN 386357v1